AAP
DNTH icon

Arax Advisory Partners’s Dianthus Therapeutics DNTH Stock Holding History

Arax Advisory Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.75K Buy
18
+13
+260% +$1.14K ﹤0.01% 4847
2026
Q1 		$420 Buy
5
+4
+400% +$232 ﹤0.01% 3442
2025
Q4 		$41 Sell
1
-52
-98% -$2.02K ﹤0.01% 3951
2025
Q3 		$2.09K Buy
+53
New +$1.35K ﹤0.01% 3106
2025
Q2 		– Sell
-32
Closed -$581 – 3086
2025
Q1 		$581 Hold
32
– – ﹤0.01% 2515
2024
Q4 		$698 Buy
+32
New +$823 ﹤0.01% 2251

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Arax Advisory Partners's DNTH Position: Q2 2026 in Review

Arax Advisory Partners increased its Dianthus Therapeutics (DNTH) stake by 260% in Q2 2026, buying an estimated $1.14K and bringing the position to 18 shares worth $1.75K. The position accounts for ﹤0.01% of the portfolio, ranked #4847.

Arax Advisory Partners first reported a position in DNTH in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.09K in Q3 2025. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Arax Advisory Partners held 18 shares of Dianthus Therapeutics worth $1.75K as of Q2 2026.
  • Arax Advisory Partners bought 13 Dianthus Therapeutics shares in Q2 2026, an estimated $1.14K.
  • Dianthus Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4847 holding.
  • Arax Advisory Partners first reported a position in Dianthus Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Arax Advisory Partners's Dianthus Therapeutics position peaked at $2.09K in Q3 2025.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.